Sino Biopharmaceutical (HK:1177) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sino Biopharmaceutical has announced positive results from a Phase III study of its innovative drug Benmelstobart, with or without Anlotinib, showing improved progression-free survival for non-small cell lung cancer patients. This advancement could provide new treatment options for those with locally advanced, unresectable Stage III NSCLC, where current options are limited. The company plans to submit a marketing application soon, aiming to expand its portfolio of cancer treatment indications.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
